OTS-167
- Generic Name
- OTS-167
Safety Study of MELK Inhibitor to Treat Patients with Advanced Breast Cancer and Triple Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Relapsed/refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- OncoTherapy Science, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02926690
- Locations
- 🇺🇸
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Weill Cornell Medicine | NewYork-Presbyterian, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath